"Atosiban application in fresh ET cycle is effective for women undergoing repeated embryo implantation failures, especially for advanced-age obese patients"

作者全名："Li, Jie; Mo, Sien; Lin, Zhong; Shi, Qiuling"

作者地址："[Li, Jie; Shi, Qiuling] Chongqing Med Univ, Coll Biomed Engn, State Key Lab Ultrasound Med & Engn, Chongqing 400016, Peoples R China; [Li, Jie; Mo, Sien; Lin, Zhong] Reprod Hosp Guangxi Zhuang Autonomous Reg, Nanning, Peoples R China; [Shi, Qiuling] Chongqing Med Univ, Sch Publ Hlth, Chongqing, Peoples R China"

通信作者："Shi, QL (通讯作者)，Chongqing Med Univ, Coll Biomed Engn, State Key Lab Ultrasound Med & Engn, Chongqing 400016, Peoples R China.; Shi, QL (通讯作者)，Chongqing Med Univ, Sch Publ Hlth, Chongqing, Peoples R China."

来源：SCIENTIFIC REPORTS

ESI学科分类：Multidisciplinary

WOS号：WOS:001134102800029

JCR分区：Q1

影响因子：3.8

年份：2023

卷号：13

期号：1

开始页：　

结束页：　

文献类型：Article

关键词：　

摘要："To assess the effect of atosiban in pregnancy outcomes of the fresh embryo transfer (ET), the retrospective cohort study was conducted. Six hundred and eighty-nine cases (using atosiban) and 1377 age and ET cycle-matched controls were collected from the January 2016 to May 2022 to perform the fresh IVF-ET cycle. The essential characteristics and pregnancy outcomes were analyzed. Conditional logistic regression analysis and subgroup analysis were performed. In the whole samples, atosiban had no effects in the pregnancy outcomes. Subgroup analyses suggested that atosiban could improve the clinical pregnancy in more than 3 ET cycles (OR 1.667, 95% CI 1.108-2.509, P = 0.014). Moreover, the improvement of clinical pregnancy was mainly present in the advanced-age women (age >= 35 years: OR 1.851, 95% CI 1.136-3.014, P = 0.013), obesity (BMI >= 24 kg/m2: OR 2.550, 95% CI 1.105-5.883, P = 0.028) and cleavage stage embryo (D3 embryo: OR 1.721, 95% CI 1.098-2.696, P = 0.018) among the repeated implantation failures (RIF). Atosiban could also improve the live birth for the obese women. Further, in the RIF, atosiban application was strongly recommended for the advanced-age infertility women, who also had the risk of obesity with the implantation of the cleavage stage embryo. In conclusion, atosiban could improve pregnancy outcomes for the advanced-age and obese women in RIF, especially while implanting the cleavage stage embryo in fresh ET cycle."

基金机构：the Self-funded research projects by Guangxi Zhuang Autonomous Region Health Commission [Z-A20220363]; Guangxi Zhuang Autonomous Region Health Commission

基金资助正文："We thank to all the clinicians, embryologists, research nurses and laboratory technicians as well as the patients in this study sincerely. And this study was funded by the Self-funded research projects by Guangxi Zhuang Autonomous Region Health Commission (Grant numbers Z-A20220363)."